Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development. When our experienced team carry out your assay by using optimized and validated protocols of safety/toxicity evaluation, our clients can benefit from the efficiency and accuracy of a dedicated facility.
Cellular adoptive immunotherapy has been shown to mediate the regression of large tumors. A limitation of this treatment is the need to isolate and expand tumor-reactive lymphocytes that preexist in the patient, which can be overcome by transducing genes encoding antitumor T-cell receptor (TCR), thus providing an alternative source of tumor-specific lymphocytes.
Although we are all aware of the benefits of the immune cell defense against diseases factors, it is also true that in some cases, severe acute and chronic damage can be inflicted on the host by these same cells. The concept behind adoptive T-cell transfer is to greatly enhance the T cell repertoire against cancer by administering tumor-reactive T cells expanded and activated in vitro. So it should be no surprise that toxicities from these cells could also be enhanced. The toxicities encountered are of four types: 1) The host immunosuppression used to enhance function and engraftment of transferred T cells can have its own side effects, 2) Vigorous T cell function immediately after administration can cause acute cytokine toxicity or “cytokine storm”, 3) expression of the target antigen on some normal tissues can cause an “on target, off tumor” autoimmune injury, and 4) Aberrant reactivities can be introduced into T cells by modification of their receptors. Evaluation of the toxicity on animal models is essential to assure the safety and right of subjects. With extensive experience on preclinical in vivo research and project management, Creative Biolabs provides TCR-T cell toxicity evaluation service by utilizing appropriate models, designing comprehensive research practices and handling high-quality in vivo studies.
Fig.1 Safety/Toxicity Evaluation of TCRs
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE